AGÕæÈ˹ٷ½

STOCK TITAN

[Form 4] VolitionRX Limited Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

On 08/01/2025, VolitionRX Ltd. (VNRX) Chief Medical Officer Andrew Retter filed a Form 4 detailing an administrative, tax-related share withholding.

  • 6,142 common shares were automatically withheld and cancelled (Transaction Code F) at an indicated price of $0.64 to satisfy tax obligations arising from the vesting of 13,069 restricted stock units that had been granted in lieu of cash compensation.
  • Following the transaction, Retter’s direct beneficial ownership totals 131,632 common shares.

No open-market purchase or sale occurred, and the tiny reduction in outstanding shares is immaterial to VNRX’s capitalization. The filing therefore carries neutral informational value regarding insider sentiment or company fundamentals.

Il 01/08/2025, il Chief Medical Officer di VolitionRX Ltd. (VNRX), Andrew Retter, ha presentato un Modulo 4 che descrive una trattenuta amministrativa di azioni legata a imposte.

  • Sono state automaticamente trattenute e annullate 6.142 azioni ordinarie (Codice Transazione F) al prezzo indicato di $0,64 per soddisfare gli obblighi fiscali derivanti dal consolidamento di 13.069 unità di azioni vincolate concesse in sostituzione della retribuzione in contanti.
  • Dopo questa operazione, la proprietà diretta e beneficiaria di Retter ammonta a 131.632 azioni ordinarie.

Non è avvenuto alcun acquisto o vendita sul mercato aperto e la riduzione minima delle azioni in circolazione è irrilevante per la capitalizzazione di VNRX. Pertanto, la comunicazione ha un valore informativo neutrale riguardo al sentiment degli insider o ai fondamentali dell’azienda.

El 01/08/2025, el Director Médico de VolitionRX Ltd. (VNRX), Andrew Retter, presentó un Formulario 4 detallando una retención administrativa de acciones relacionada con impuestos.

  • Se retuvieron y cancelaron automáticamente 6,142 acciones comunes (Código de Transacción F) a un precio indicado de $0.64 para cumplir con las obligaciones fiscales derivadas de la consolidación de 13,069 unidades restringidas de acciones otorgadas en lugar de compensación en efectivo.
  • Tras la transacción, la propiedad directa y beneficiaria de Retter suma 131,632 acciones comunes.

No se realizó ninguna compra o venta en el mercado abierto y la pequeña reducción en las acciones en circulación es insignificante para la capitalización de VNRX. Por lo tanto, la presentación tiene un valor informativo neutral respecto al sentimiento interno o los fundamentos de la empresa.

2025ë…� 8ì›� 1ì�, VolitionRX Ltd.(VNRX)ì� 최고 ì˜ë£Œ ì±…ìž„ìž� Andrew Retterê°€ 세금 ê´€ë � ì£¼ì‹ ì›ì²œì§•수ì—� ê´€í•� Form 4ë¥� 제출했습니다.

  • 현금 ë³´ìƒ ëŒ€ì‹� ë¶€ì—¬ëœ 13,069 제한 ì£¼ì‹ ë‹¨ìœ„ì� 권리 확정ì—� 따른 세금 ì˜ë¬´ë¥� 충족하기 위해 6,142 보통주가 ìžë™ìœ¼ë¡œ ì›ì²œì§•수 ë°� 취소ë˜ì—ˆìŠµë‹ˆë‹�(거래 코드 F), 표시 ê°€ê²©ì€ $0.64입니ë‹�.
  • 거래 í›� Retterì� ì§ì ‘ì ì¸ 실질 소유 ì£¼ì‹ ìˆ˜ëŠ” 131,632 보통주입니다.

공개 시장ì—서ì� 매매ëŠ� 없었으며, 발행 주ì‹ì� 미미í•� ê°ì†ŒëŠ� VNRXì� ìžë³¸ê¸ˆì— í� ì˜í–¥ì� 미치지 않습니다. ë”°ë¼ì„� ì� ì‹ ê³ ëŠ� ë‚´ë¶€ìž� 심리ë‚� 회사 기본 사항ì—� 대í•� 중립ì �ì� ì •ë³´ 가치를 가집니ë‹�.

Le 01/08/2025, le directeur médical de VolitionRX Ltd. (VNRX), Andrew Retter, a déposé un formulaire 4 détaillant une retenue d’actions administrative liée aux impôts.

  • 6 142 actions ordinaires ont été automatiquement retenues et annulées (code de transaction F) à un prix indiqué de 0,64 $ pour satisfaire aux obligations fiscales découlant de l’acquisition de 13 069 unités d’actions restreintes attribuées en lieu et place d’une rémunération en espèces.
  • Après la transaction, la propriété bénéficiaire directe de Retter s’élève à 131 632 actions ordinaires.

Aucun achat ou vente sur le marché ouvert n’a eu lieu, et la légère réduction des actions en circulation est sans conséquence pour la capitalisation de VNRX. Le dépôt a donc une valeur informative neutre concernant le sentiment des initiés ou les fondamentaux de l’entreprise.

Am 01.08.2025 reichte der Chief Medical Officer von VolitionRX Ltd. (VNRX), Andrew Retter, ein Formular 4 ein, das eine administrative, steuerlich bedingte Aktieneinbehaltung beschreibt.

  • 6.142 Stammaktien wurden automatisch einbehalten und storniert (Transaktionscode F) zu einem angegebenen Preis von $0,64, um Steuerverpflichtungen im Zusammenhang mit der Vesting von 13.069 Restricted Stock Units zu erfüllen, die anstelle von Barvergütungen gewährt wurden.
  • Nach der Transaktion beträgt Retters direkte wirtschaftliche Eigentümerschaft 131.632 Stammaktien.

Es fand kein Kauf oder Verkauf am offenen Markt statt, und die geringe Reduzierung der ausstehenden Aktien ist für die Kapitalisierung von VNRX unerheblich. Die Meldung hat daher einen neutralen Informationswert hinsichtlich der Insiderstimmung oder der Unternehmensgrundlagen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR Routine tax-withholding; no cash sale or purchase, insider still holds 132k shares—neutral signal for VNRX investors.

Code F events simply cover withholding taxes upon equity award settlement. Retter’s 6,142-share cancellation represents roughly 4.7% of the RSUs vested and is immaterial versus VolitionRX’s float. Because shares are cancelled rather than sold, there is no selling pressure; the slight share count reduction is fractionally accretive. Overall, the disclosure neither strengthens nor weakens the investment thesis.

Il 01/08/2025, il Chief Medical Officer di VolitionRX Ltd. (VNRX), Andrew Retter, ha presentato un Modulo 4 che descrive una trattenuta amministrativa di azioni legata a imposte.

  • Sono state automaticamente trattenute e annullate 6.142 azioni ordinarie (Codice Transazione F) al prezzo indicato di $0,64 per soddisfare gli obblighi fiscali derivanti dal consolidamento di 13.069 unità di azioni vincolate concesse in sostituzione della retribuzione in contanti.
  • Dopo questa operazione, la proprietà diretta e beneficiaria di Retter ammonta a 131.632 azioni ordinarie.

Non è avvenuto alcun acquisto o vendita sul mercato aperto e la riduzione minima delle azioni in circolazione è irrilevante per la capitalizzazione di VNRX. Pertanto, la comunicazione ha un valore informativo neutrale riguardo al sentiment degli insider o ai fondamentali dell’azienda.

El 01/08/2025, el Director Médico de VolitionRX Ltd. (VNRX), Andrew Retter, presentó un Formulario 4 detallando una retención administrativa de acciones relacionada con impuestos.

  • Se retuvieron y cancelaron automáticamente 6,142 acciones comunes (Código de Transacción F) a un precio indicado de $0.64 para cumplir con las obligaciones fiscales derivadas de la consolidación de 13,069 unidades restringidas de acciones otorgadas en lugar de compensación en efectivo.
  • Tras la transacción, la propiedad directa y beneficiaria de Retter suma 131,632 acciones comunes.

No se realizó ninguna compra o venta en el mercado abierto y la pequeña reducción en las acciones en circulación es insignificante para la capitalización de VNRX. Por lo tanto, la presentación tiene un valor informativo neutral respecto al sentimiento interno o los fundamentos de la empresa.

2025ë…� 8ì›� 1ì�, VolitionRX Ltd.(VNRX)ì� 최고 ì˜ë£Œ ì±…ìž„ìž� Andrew Retterê°€ 세금 ê´€ë � ì£¼ì‹ ì›ì²œì§•수ì—� ê´€í•� Form 4ë¥� 제출했습니다.

  • 현금 ë³´ìƒ ëŒ€ì‹� ë¶€ì—¬ëœ 13,069 제한 ì£¼ì‹ ë‹¨ìœ„ì� 권리 확정ì—� 따른 세금 ì˜ë¬´ë¥� 충족하기 위해 6,142 보통주가 ìžë™ìœ¼ë¡œ ì›ì²œì§•수 ë°� 취소ë˜ì—ˆìŠµë‹ˆë‹�(거래 코드 F), 표시 ê°€ê²©ì€ $0.64입니ë‹�.
  • 거래 í›� Retterì� ì§ì ‘ì ì¸ 실질 소유 ì£¼ì‹ ìˆ˜ëŠ” 131,632 보통주입니다.

공개 시장ì—서ì� 매매ëŠ� 없었으며, 발행 주ì‹ì� 미미í•� ê°ì†ŒëŠ� VNRXì� ìžë³¸ê¸ˆì— í� ì˜í–¥ì� 미치지 않습니다. ë”°ë¼ì„� ì� ì‹ ê³ ëŠ� ë‚´ë¶€ìž� 심리ë‚� 회사 기본 사항ì—� 대í•� 중립ì �ì� ì •ë³´ 가치를 가집니ë‹�.

Le 01/08/2025, le directeur médical de VolitionRX Ltd. (VNRX), Andrew Retter, a déposé un formulaire 4 détaillant une retenue d’actions administrative liée aux impôts.

  • 6 142 actions ordinaires ont été automatiquement retenues et annulées (code de transaction F) à un prix indiqué de 0,64 $ pour satisfaire aux obligations fiscales découlant de l’acquisition de 13 069 unités d’actions restreintes attribuées en lieu et place d’une rémunération en espèces.
  • Après la transaction, la propriété bénéficiaire directe de Retter s’élève à 131 632 actions ordinaires.

Aucun achat ou vente sur le marché ouvert n’a eu lieu, et la légère réduction des actions en circulation est sans conséquence pour la capitalisation de VNRX. Le dépôt a donc une valeur informative neutre concernant le sentiment des initiés ou les fondamentaux de l’entreprise.

Am 01.08.2025 reichte der Chief Medical Officer von VolitionRX Ltd. (VNRX), Andrew Retter, ein Formular 4 ein, das eine administrative, steuerlich bedingte Aktieneinbehaltung beschreibt.

  • 6.142 Stammaktien wurden automatisch einbehalten und storniert (Transaktionscode F) zu einem angegebenen Preis von $0,64, um Steuerverpflichtungen im Zusammenhang mit der Vesting von 13.069 Restricted Stock Units zu erfüllen, die anstelle von Barvergütungen gewährt wurden.
  • Nach der Transaktion beträgt Retters direkte wirtschaftliche Eigentümerschaft 131.632 Stammaktien.

Es fand kein Kauf oder Verkauf am offenen Markt statt, und die geringe Reduzierung der ausstehenden Aktien ist für die Kapitalisierung von VNRX unerheblich. Die Meldung hat daher einen neutralen Informationswert hinsichtlich der Insiderstimmung oder der Unternehmensgrundlagen.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Retter Andrew

(Last) (First) (Middle)
1489 WEST WARM SPRINGS ROAD,
SUITE 110

(Street)
HENDERSON NV 89014

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Medical Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/01/2025 F 6,142(1) D $0.64 131,632 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 13,069 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.
Remarks:
/s/ Andrew Retter 08/05/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Volitionrx

NYSE:VNRX

VNRX Rankings

VNRX Latest News

VNRX Latest SEC Filings

VNRX Stock Data

66.55M
83.43M
18.4%
20.49%
0.35%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
United States
HENDERSON